- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/08 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
Patent holdings for IPC class C07D 239/08
Total number of patents in this class: 14
10-year publication summary
|
0
|
3
|
2
|
0
|
1
|
2
|
0
|
0
|
0
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | 810 |
2 |
| Melior Pharmaceuticals I, Inc. | 26 |
2 |
| Shandong Danhong Pharmaceutical Co., Ltd. | 23 |
2 |
| Merck & Co., Inc. | 424 |
1 |
| Wisconsin Alumni Research Foundation | 3849 |
1 |
| Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. | 62 |
1 |
| Korea Research Institute of Chemical Technology | 1347 |
1 |
| MethylGene Inc. | 47 |
1 |
| Purdue Pharma L.P. | 509 |
1 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 811 |
1 |
| ESSA Pharma Inc. | 42 |
1 |
| Other owners | 0 |